Gilead Sciences ((GILD)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Gilead Sciences is conducting a Phase 2 clinical study titled A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-1427 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC). The study aims to evaluate the effectiveness of GS-1427 in treating moderate to severe ulcerative colitis by comparing it to a placebo over a 12-week period. The primary goal is to assess clinical response at Week 12.
The intervention being tested is GS-1427, an orally administered drug, with the purpose of treating ulcerative colitis. The study also includes a placebo group for comparison.
This interventional study is randomized with a sequential intervention model. It employs double masking, meaning both participants and investigators are unaware of the treatment allocations. The primary purpose of the study is treatment.
The study began on March 27, 2024, with an estimated completion date not yet provided. The last update was submitted on June 23, 2025. These dates are crucial for tracking the study’s progress and potential market entry.
The outcome of this study could significantly impact Gilead Sciences’ stock performance, as a successful treatment for ulcerative colitis could open up new revenue streams. This development is particularly relevant in the competitive pharmaceutical industry, where advancements in treatment options can shift market dynamics.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.